Adaptive Biologix, Inc.
Records under this name other than patents Adaptive Biologix, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to Adaptive Biologix, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,191,780 | Extracellular matrix compositions for the treatment of cancer or immunological diseases Lapsed on the fee record Ended Dec 7, 2025 · USPTO record | Lapsed on the fee record | Ended Dec 7, 2025 | USPTO record |
| US 9,506,038 | Extracellular matrix compositions for the treatment of cancer Lapsed on the fee record Ended Nov 29, 2024 · USPTO record | Lapsed on the fee record | Ended Nov 29, 2024 | USPTO record |
| US 10,675,303 | Extracellular matrix compositions for the treatment of cancer Lapsed on the fee record Ended Jun 9, 2024 · USPTO record | Lapsed on the fee record | Ended Jun 9, 2024 | USPTO record |
| US 9,034,312 | Extracellular matrix compositions for the treatment of cancer Lapsed on the fee record Ended May 19, 2023 · USPTO record | Lapsed on the fee record | Ended May 19, 2023 | USPTO record |
| US 10,143,708 | Extracellular matrix compositions for the treatment of cancer Formerly held Lapsed on the fee record Ended Dec 4, 2022 · USPTO record | Lapsed on the fee record | Ended Dec 4, 2022 | USPTO record |
| US 8,852,637 | Extracellular matrix compositions for the treatment of cancer Lapsed on the fee record Ended Oct 7, 2022 · USPTO record | Lapsed on the fee record | Ended Oct 7, 2022 | USPTO record |